Dr. Bradt is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
One Main Street
suite 700
Cambridge, MA 02142Phone+1 339-223-2098
Education & Training
- San Antonio Uniformed Services Health Education ConsortiumInternship, Transitional Year, 1998 - 1999
- University of Kansas School of MedicineClass of 1997
Certifications & Licensure
- TX State Medical License 1998 - 2025
Publications & Presentations
PubMed
- 29 citationsA randomized, placebo-controlled phase 3 trial of the PI3Kδ inhibitor leniolisib for activated PI3Kδ syndrome.V Koneti Rao, Sharon Webster, Anna Šedivá, Alessandro Plebani, Catharina Schuetz
Blood. 2023-03-02 - 5 citationsInterim analysis: Open-label extension study of leniolisib for patients with APDS.V Koneti Rao, Elaine Kulm, Anna Šedivá, Alessandro Plebani, Catharina Schuetz
The Journal of Allergy and Clinical Immunology. 2024-01-01 - 4 citationsComparative risk of bloodstream infection in hospitalized patients receiving intravenous medication by open, point-of-care, or closed delivery systemsCatherine J. Mercaldi, Stephan Lanes, Jason Bradt
American Journal of Health-System Pharmacy. 2013-06-01
Journal Articles
- Leniolisib treatment for people with activated PI3K delta syndrome (APDS): a plain language summary of the phase 3 studyElaine Kulm, Sharon Webster, Anna Šedivá, Alessandro Plebani, Catharina Schuetz, Niall Conlon6, Virgil A.S.H. Dalm, Julia Körholz, Vassilios Lougaris, Jo Luscombe &..., Future Rare Disease, 7/9/2024
- Long-term treatment with selective PI3Kδ inhibitor leniolisib in adults with activated PI3Kδ syndromeV. Koneti Rao, Elaine Kulm, Jennifer Grossman, David Buchbinder, Hey Chong, Jason Bradt, Sharon Webster, Anna Šedivá, Virgil A. Dalm, Gulbu Uzel, Blood Advances, 6/25/2024
- Long-Term Treatment With Selective PI3Kδ Inhibitor Leniolisib in Adults With Activated PI3Kδ SyndromeV. Koneti Rao, Elaine M Kulm, Jennifer K Grossman, David K Buchbinder, Hey Chong, Jason Bradt, Sharon Webster, Anna Šedivá, Virgil A. Dalm, Gulbu Uzel, Blood Advances, 4/9/2024
- Join now to see all
Abstracts/Posters
- Interim Analysis of Safety and Hematological Parameters of an Ongoing Long-Term Open-Label Extension Study of Investigational PI3Kδ Inhibitor Leniolisib for Patients w...V. Koneti Rao, Sharon Webster, Anna Sediva, Alessandro Plebani, Catharina Schuetz, Anna Shcherbina, Virgil A.S.H. Dalm, Antonino Trizzino, Yulia Zharankova, El..., Blood, 11/15/2022
- Phase 3 Placebo-Controlled, Randomized Clinical Trial Outcomes of PI3K Delta Inhibitor Leniolisib in Patients with Activated PI3K Delta Syndrome (APDS/PASLI)V. Koneti Rao*1, Sharon Webster, Anna Šedivá, Alessandro Plebani, Catharina Schütz, Anna Shcherbina, Niall Conlon, Tanya Coulter, Virgil Dalm, Antonino Trizzino, Yulia..., 13th Annual Meeting of the Clinical Immunology Society, Charlotte, NC, 4/1/2022
- Phase 3 Placebo-Controlled, Randomized Clinical Trial Outcomes of PI3K Delta Inhibitor Leniolisib in Patients with Activated PI3K Delta Syndrome (APDS/PASLI)V. Koneti Rao, Sharon Webster, Anna Šedivá, Alessandro Plebani, Catharina Schütz, Anna Shcherbina, Niall Conlon, Tanya Coulter, Virgil Dalm, Antonino Trizzino, Yulia Z..., Selected Abstracts from the 13th Annual Meeting of the Clinical Immunology Society: 2022 Annual Meeting: Immune Deficiency and Dysregulation North American Conference, Charlotte, North Carolina, 3/31/2022
- Join now to see all
Press Mentions
- Lundbeck to Present Data on Alzheimer’s, Epilepsy and Movement Disorder Medicines at AANApril 11th, 2016
- Death of Spy Who Ingested Polonium Spurs Drug CompaniesJanuary 25th, 2007
- American Academy of Neurology and Lundbeck Offer New Clinical Research Training Fellowships in Epilepsy, Parkinson’sJune 6th, 2017
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: